Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

328
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
328
Drug Therapy01:28

Drug Therapy

107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
107
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

378
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
378
The Placebo Effect01:54

The Placebo Effect

6.3K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.3K
Bipolar Disorder01:30

Bipolar Disorder

152
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
152
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

803
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
803

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of perceived stress on adherence to the Mediterranean diet, eating behaviour and quality of life in a group of Italian adolescents.

International journal of food sciences and nutrition·2026
Same author

Ketogenic diet for epilepsy and obesity: Is it the same?

Nutrition, metabolism, and cardiovascular diseases : NMCD·2024
Same author

Emotional processing subtypes in bipolar disorder: A cluster analysis.

Journal of affective disorders·2020
Same author

Subjective response to antipsychotics in bipolar disorders: A review of a neglected area.

European psychiatry : the journal of the Association of European Psychiatrists·2019
Same author

Fremanezumab for the prevention of chronic and episodic migraine.

Drugs of today (Barcelona, Spain : 1998)·2019
Same author

Characterization of Mood Instability through Bipolar Disorders: A cluster-analytic approach using weekly prospective life-chart methodology.

European psychiatry : the journal of the Association of European Psychiatrists·2019
Same journal

Consensus by design: Conflict of interest and the intravenous ketamine Delphi guidelines.

Journal of affective disorders·2026
Same journal

Impaired crying despite preserved emotional experience under antidepressant treatment: An under-recognized clinical phenomenon.

Journal of affective disorders·2026
Same journal

Corrigendum to "Effects of neuronavigation-guided rTMS on serum BDNF, TrkB and VGF levels in depressive patients with suicidal ideation" [J. Affect. Disord. 323 (2023) 617-623].

Journal of affective disorders·2026
Same journal

Transcutaneous vagus nerve stimulation enhances reward-effort efficiency in severe major depressive disorder.

Journal of affective disorders·2026
Same journal

Age-varying associations between attitudes toward suicide and suicidal ideation in Chinese psychiatric outpatients.

Journal of affective disorders·2026
Same journal

Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed.

Journal of affective disorders·2026
See all related articles

Related Experiment Video

Updated: Sep 18, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.5K

Mood stabilizers: Insights from users' perceptions.

M F Tagni1, S A Strejilevich1, S Camino1

  • 1AREA, Asistencia e Investigación en Trastornos del Ánimo, Buenos Aires, Argentina.

Journal of Affective Disorders
|June 22, 2025
PubMed
Summary
This summary is machine-generated.

Patient satisfaction with mood stabilizers (MSAs) for bipolar disorder (BD) is high, with lamotrigine generally rated higher. Emotional and psychological side effects significantly predict dissatisfaction, highlighting the importance of patient-reported outcomes in treatment decisions.

Keywords:
Bipolar disorderEmotional bluntingMood stabilizersPsychological side effectsUsers' opinions

More Related Videos

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

823
How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
08:50

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

9.4K

Related Experiment Videos

Last Updated: Sep 18, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.5K
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

823
How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants
08:50

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

9.4K

Area of Science:

  • Psychiatry and Pharmacology
  • Patient-Reported Outcomes Research
  • Mental Health Treatment

Background:

  • Subjective perceptions of psychopharmacological treatment strongly influence patient outcomes and adherence.
  • Mood stabilizing agents (MSAs) are crucial for bipolar disorders (BDs), yet patient experiences are under-researched.
  • Understanding patient perspectives is vital for optimizing BD treatment.

Purpose of the Study:

  • To explore and compare user-reported data on four first-line MSAs for bipolar disorder.
  • To identify predictors of treatment satisfaction and dissatisfaction among patients with BD.
  • To evaluate patient experiences with lithium, lamotrigine, valproate, and quetiapine.

Main Methods:

  • Quantitative analysis of 200 online posts from individuals on long-term MSA treatment for BD.
  • Analysis of demographical, clinical, somatic, and emotional/psychological side effects.
  • Statistical modeling to compare satisfaction ratings and identify predictors of dissatisfaction.

Main Results:

  • Overall high satisfaction reported with MSAs.
  • Lamotrigine received higher satisfaction ratings than quetiapine and valproate.
  • Obsessive-compulsive symptoms, emotional hyperreactivity, cognitive symptoms, anxiety, weight gain, and GI symptoms predicted dissatisfaction.

Conclusions:

  • Emotional and psychological side effects significantly impact treatment dissatisfaction with MSAs.
  • Patient subjective experiences are critical for both research and clinical decision-making in BD treatment.
  • Future research and clinical practice should prioritize patient-reported outcomes for MSAs.